Date of Preparation: 8/1997



Yüklə 231,71 Kb.
səhifə1/4
tarix04.11.2017
ölçüsü231,71 Kb.
#30662
  1   2   3   4

Silvana Martino, D.O.

Curriculum Vitae

Page


SILVANA MARTINO, D.O., F.A.C.O.I.

CURRICULUM VITAE


OFFICE ADDRESS:
The Angeles Clinic And Research Institute

2001 Santa Monica Boulevard, Suite 560W 11818 Wilshire Boulevard, Suite #200

Santa Monica, California 90404 Los Angeles, CA 90025
Telephone: (310) 582-7900 Telephone: (310) 231-2192

Facsimile: (310) 582-7918



PERSONAL DATA:
Born   September 7, 1948, Italy.

Spouse – John R. Hill



EDUCATION:
1970 B.S., Degree, Wayne State University, Detroit, MI.

1973 D.O., Degree, Michigan State University College of Osteopathic Medicine, East Lansing, MI.


TRAINING:
1973   1974 Internship, Detroit Osteopathic Hospital, Detroit, MI.

1974   1977 Residency in Internal Medicine, Botsford Hospital, Farmington, MI.

1977   1979 Fellowship in Oncology, Wayne State University School of Medicine, Detroit, MI.

FACULTY APPOINTMENTS:
1979   1988 Assistant Professor, Department of Medicine, Division of Hematology and Oncology,

Wayne State University School of Medicine, Detroit, MI

1988   1993 Associate Professor, Department of Medicine, Division of Hematology and Oncology,

Wayne State University School of Medicine, Detroit, MI

1999 - 2003 Faculty, The John W. Wayne Cancer Institute

2003 Adjunct Faculty, The John W. Wayne Cancer Institute

2003 Clinical Associate Professor of Medicine, Keck School of Medicine, University of Southern

California, Los Angeles, CA

2004 -2011 Director, Breast Cancer Program, The Angeles Clinic and Research Institute, Santa Monica, CA

2011 Director, Breast Cancer Research and Education, The Angeles Clinic Foundation,

Santa Monica, CA
HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:
1979 - 1993 Full time staff, Harper Grace Hospitals, Detroit, MI

1979   1993 University Affiliate, Section of Oncology, Department of Medicine, Hutzel Hospital, Detroit, MI

1979   1983 Coordinator, Oncology Housestaff, Harper Grace Hospitals, Detroit, MI

1981 - 1986 Clinical Advisor, Breast Cancer Prognostic Study, Michigan Cancer Foundation, Detroit, MI

1983   1993 University Affiliate, Department of Medicine, Detroit Receiving Hospital, Detroit, MI

1984   1985 Michigan Cancer Foundation Volunteer and Community Service Committee

1987   1993 Medical Director, Breast Cancer Prevention Program, Wayne State University and Harper Grace Hospital, Detroit MI

1989   1992 Adjunct Appointment Graduate Faculty Department of Medicine, Wayne State Univ, Det, MI

1990   1992 Service Chief, Hematology/Oncology Division, Section of Breast, Lung and Biologic Response Modifiers, Wayne State University, Detroit, MI

1992 - 1993 Service Chief, Section of Breast Cancer, Hematology/Oncology Division, Wayne State

University, Detroit, MI

1993 - 1997 Medical Director, Westlake Comprehensive Breast Center, Westlake, CA

1997 - 1999 Medical Director, The Breast Center - Van Nuys, CA

1998 - 1999 Member Steering Committee for NCIC - CTR trial, PV. 1 Idoxifene

1999 - Present John Wayne Cancer Institute, Santa Monica, CA

2000 - Present Saint John’s Health Center, Santa Monica, CA

2002 - Present Santa Monica/UCLA Hospital, Santa Monica, CA

2002 - 2004 Century City Hospital, Century City, CA

2003 – 2004 Member, Infection Control Committee, Santa Monica/UCLA Hospital, Santa Monica, CA

2003 - 2007 Member, Cancer Committee, St. John’s Hospital, Santa Monica, CA



MAJOR PROFESSIONAL SOCIETIES:
American Osteopathic Association

American College of Osteopathic Internists

American Society of Clinical Oncology

Michigan Association of Osteopathic Physicians and Surgeons (until 1990)

Southwest Oncology Group

International Association for Breast Cancer Research

American Association for the Advancement of Sciences

American Society of Preventive Oncology

American Association For Cancer Research, Inc.

LICENSURE AND BOARD CERTIFICATION:
Licensure States of Michigan, West Virginia and California

American Osteopathic Board of Internal Medicine, 1984

American Osteopathic Board of Oncology, 1984

GOOD CLINICAL PRACTIVE (GCP) TRAINING:
NIH online training – Protecting Human Research Participants (07Aug2009)

HONORS AND AWARDS:
1992 Fellow, American College of Osteopathic Internists

1994 Listed in The Best Doctors In America. Woodward/White Inc. Publishers

1996 Listed in The Best Doctors in America: Pacific Region. Woodward/White Inc. Publishers

1997 Phillips Medal of Public Service: Ohio University-COM

1997 Certificate of Merit, American Cancer Society

1998 Listed in The Best Doctors in America. Woodward/White Inc. Publishers, 4th Edition

1998-2000 Certificate of Merit, American Cancer Society

1998-2000 Listed in Who’s Who in Medicine and Healthcare

1999 Listed in Who’s Who in America, Millenium Edition

1999 Listed in Who’s Who in the World, Millenium Edition

1999 Listed in Who’s Who in Science and Engineering, Millenium Edition

2001-2005 Listed in Who’s Who in America

2001 Honorary Board Member, American Cancer Society, Greater Conejo Valley

2002 Listed in Best Doctors in America. Woodward/White Inc. Publishers.



  1. Listed in Who’s Who of American Women

2003 Listed in Who’s Who in Science and Engineering (7th Edition)

2004 Listed in Who’s Who in Medicine and Healthcare (5th Edition)

2005 3rd Prize Award for abstract, American College of Obstetricians and Gynecologists 53rd Annual Clinical Mtg

2005 Listed in Who’s Who of American Women: Silver Anniversary Edition

2006 Listed in Who’s Who in Medicine and Healthcare (6th Edition)

2006 Celebration of Excellence Award, The Wellness Community:Valley/Ventura

2007 Researcher of the Year award,The American College of Ostopathic Internists

2007-2009 Listed in America’s Top Oncologists by the Consumer’s Research Council of America

2009-2010 Listed in Who’s Who in Medicine & Healthcare (7th Edition)

2010-2011 Listed in Who’s Who in America

2010 Listed in Who’s Who, The Global Directory, Top Doctor

2010-2011 Listed in Who’s Who of American Women

2011-2012 Listsed in Who’s Who in Medicine & Healthcare

2012 Listed in Southern California Super Doctors



SERVICE:
Journal/Editorial Activity:
Reviewer for Breast Cancer Research and Treatment

Reviewer for Journal of Clinical Oncology



Other Professionally Related Service:
1981   1982 Oncology Department Salary Committee, Wayne State University, Detroit, MI

1980   1984 Oncology Department Education Committee, Wayne State University, Detroit MI

1982   1983 Department of Medicine Housestaff Selection Committee

1983   1984 Human Sexuality Committee, Wayne State University, Detoit MI

1984   1987 Oncology Fellowship Committee, Wayne State University, Detroit MI

1984   1987 Wayne State Medical School Promotions Review Committee, Detroit MI

1984   1992 Human Investigation Committee, Wayne State University, Detroit MI

1989   1992 Wayne State Univ, Department of Medicine, Promotions & Tenure Committee, Detroit, MI

1991 Wayne State Univ, Department of Medicine, Compensation Committee, Detroit MI

National and International Boards and Committees:
1981   Present SWOG Breast Committee

1981   1996 SWOG Breast Cancer Working Group

1984 - 1986 Chairman: American College of Osteopathic Internists, Hematology and Oncology Section

1985 - 1992 Consultant: American Osteopathic Board of Internal Medicine, Subspecialty of

Oncology

1987 - 1992 Co-Chairman: SWOG Cancer Control Research Committee

1987 - Present SWOG Executive Committee of the Cancer Control Research Committee

1989 National Cancer Institute ad hoc Grant Review Committee Minority Based Community Clinical Oncology Program, March 14-16, 1989

1989 - Present SWOG Cancer Control Liaison to Breast Committee

1990 Co Chair, National Cancer Institute Grant Review Committee for Community Clinical Oncology Program, November 28 30, 1990.

1990   1991 Program Committee for the American College of Osteopathic Internists Convention and Scientific Seminar.

1990 - 1992 Member SWOG Minority Research Subcommittee

1991 - Present Advisory Board; SWOG Committee on Women's Health and Special Populations

1992 Chair - National Cancer Institute Grant Review Committee, RO1, Breast Cancer in the Elderly, February 17-18, 1992.

1992 - 2000 Chairman; SWOG Breast Committee.

1993 National Cancer Institute Review Committee for RFA CA-93-33

1994 NCI - Review Committee for University of Pennsylvania Cancer Center Core Grant

1993 - 1994 Board of Scientific Advisors: International Breast Cancer Research Foundation, Inc.

1995 - 1998 SWOG Data and Safety Montoring Committee

1999   2002 Reviewer for The Susan G. Komen Breast Cancer Foundation National Grant

Program

2002   2006 Member, Oncology Drugs Advisory Committee (ODAC), Food & Drug Administration



2004   2006 Chairman, Oncology Drugs Advisory Committee (ODAC), Food & Drug Administration


State and Local Boards and Committees:
1980   1990 Harper Hospital Emergency Room Committee (Detroit, Michigan)

1984   1990 DMCIOAD Board of Trustees (Detroit, Michigan)

1987   1988 Advisory Committee for community Health Programs, Harper Grace Hospitals (Detroit, Michigan)

1987   1993 Cancer Committee for Harper Hospital (Detroit, Michigan)

1994 - 1995 American Cancer Society - Board of Directors, Ventura County

1995 - 1997 Cancer Committee for Westlake Medical Center

1995 - 1997 Insitutional Review Board for Westlake Medical Center

1995 - 1997 Cancer Committee for Los Robles Regional Medical Center

1995 - 1998 American Cancer Society/Greater Conjeo Valley Unit, V.P. Volunteer Development

1996 - 1999 Wellness Community Valley/Ventura Board of Directors

1996   Present Wellness Community Valley/Ventura member of Professional Advisory Board

2007 - Present Persian American Cancer Institute (PACI)

2008 - Present California Breast Cancer Research Program, “Intraductal Therapy of DCIS: A Presurgery Study”, Data Safety Monitoring Board (Santa Monica, CA)
TEACHING:
Wayne State University: 1979 - 1993 - Medical Oncology, General Medicine, and Physical Diagnosis.
Courses Taught at Wayne State University:
Undergraduate:
Prevention and Cancer Control, WSU, Dept. of Biological Sciences, April 1987 and 1988.

Teaching (continued):
Graduate:
Diet in Breast Cancer Prevention, WSU, Dept. of Metabolism and Nutrition, April, 1987.
Graduate Professional School:


  1. "Sexual Dysfunction of Breast Cancer", WSU Medical School year 2 class. (Yearly 1984 1990).




  1. "Breast Cancer", Oncology Section of the Disease Processes and Therapeutic Course for the Doctor of Pharmacy Candidates WSU, October 1985 and February 1988.




  1. "Breast Cancer", Diet and Nutrition in Breast Cancer. Cancer Biology Ph.D. Program Course, Wayne State University, November 25, 1991.




  1. "Breast Cancer", Chemotherapy. Cancer Biology Ph.D. Program Course, Wayne State University, December 2, 1991.




  1. "Sexual Dysfunction of Breast Cancer", WSU Medical School, Year 2 class, September 1992.




  1. "Chemotherapy and Dietary Prevention of Breast Cancer", Cancer Control Course (CB.725), Wayne State University, January 1993.




  1. The John Wayne Cancer Institute Clinical rotation for: General Surgical Oncology Fellows and Breast Surgical Oncology fellows, 1999 – On.




  1. University of Southern California (USC): Clinical rotation for: Medical Oncology Fellows, 2003 - 2008



Essays/Theses/Dissertations Directed:
1979 – 1993 Member of Dissertation Committee for Diane Lancaster, Ph.D. Candidate, Department of Nursing.
Other:
1979 – 1993 Rounding in Internal Medicine, Medical Oncology and Physical Diagnosis at Harper

Hospital, Detroit, Michigan.



GRANT SUPPORT:
Funded:
1982 – 1984 Schering Corporation Study C82 034 02 Phase II Trial of SCH 30500 Interferon Alpha2 in Carcinoma of the Breast, Principal Investigator.
1985 – 1987 Phase I Study of Recombinant Beta Interferon (IFN beta Ser 17), Ceta Shell Corporation. Co Investigator.
1986 – 1989 Upjohn Company, R 9134, Phase II Study of Menogaril as First Line Therapy in Advanced Breast Cancer   ($40,000), Principal Investigator.
1987 TAP Pharmaceutical, Leuprolide vs. Leuprolide + Tamoxifen in Premenopausal Breast Cancer Patients with Metastatic Disease   ($10,000), Co Investigator.
987 Wayne State University Research Stimulation Fund, Prolactin Changes in High Risk Breast Cancer Patients on Low Fat Diet   ($10,000), Principal Investigator.
1987 – 1989 RO1 (NCI) Breast Cancer Cell Kinetics   ($10,000), Co Investigator.
1987 – 1988 Breast Cancer Prevention Program, Marilyn Smith Breast Cancer Research Fund. Private Donation  ($100,000), Principal Investigator.
1989 Breast Cancer Prevention Program, Florence L. Graham, Private Donation, ($134,000), Principal Investigator.
1989 Breast Cancer Prevention Program, Michigan Ladies Auxilliary Donation, ($7,945), Principal Investigator.
1989 – 1990 Bio Science Phase II Evaluation of WR 2721 & Platinum for Refractory Metastatic Breast Cancer, ($14,000), Co Investigator.
1988 – 1992 NCI, Low Fat Diet in Stage II Breast Cancer Randomized Study. ($680,569); Co Investigator; (Sub-contract).
1991 – 1992 ACS, Institutional Application Clinical Oncology Fellowship ($110,000), Co-Investigator, 5% effort.
1991 – 1999 NCI-NSABP - A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer (sub-contract) $1300\patient.
1993 – 1993 NCI, SWOG Breast Cancer Committee ($15,567), Principal Investigator.
1993 – 1996 NCI - Women's Intervention Nutritional Study (WINS) (sub-contract) $1,700\patient.
1994 – 1994 NCI, SWOG Breast Cancer Committee ($16,525), Principal Investigator.
1995 – 1995 NCI, SWOG Breast Cancer Committee ($16,328), Principal Investigator.
1996 – 1996 NCI, SWOG Breast Cancer Committee ($16,574), Principal Investigator.
1997 – 1997 NCI, SWOG Breast Cancer Committee ($16,894), Principal Investigator.
1998 – 1998 NCI, SWOG Breast Cancer Committee ($9,905), Principal Investigator.
1999 – 1999 NCI, SWOG Breast Cancer Committee ($9,024), Principal Investigator.
1999 – 2001 RPR, Neoadjuvant Epirubicin and Taxotere weekly for Breast Cancer with biological correlates (Per patient payment).
1999 – 2001 Pharmacia, Neoadjuvant Epirubicin and Taxotere weekly for Breast Cancer with biological correlates (Per patient payment).
1999– Present NCI, SWOG and CTSU Trials (Per patient payment).
2000 – 2000 NCI, SWOG Breast Cancer Committee ($15,619), Principal Investigator.
2000 – 2003 NCI, Pharmacology of Anticancer Drugs in Advanced age; [Derek Raghavan, PI for SWOG, ($1,212,304)], Co-Investigator 2% salary.
June 2001 American BioScience, Inc., A Controlled Randomized Phase III, Multicenter, Open Label Study of ABI-007 (A Cremophor®-Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol® in Patients With Metastatic Breast Cancer (Per patient payment).
August 2002 Novartis Pharmaceuticals, An Open-Label, Randomized, Multicenter Study to Evauate the Use of Zolecronic Acid in the Prevention of Cancer Treatment-related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy (Per patient payment).
2003 – 2004 Trio Clinical Research, LLC, An Open-Label, Phase II Trial of the Immunological Response Rate, Safety, and Tolerability of THERATOPE Vaccine in Subjects with Metastatic Breast Cancer Undergoing Treatment with Aromatase Inhibitors or Faslodex (Per patient payment).
2007 Pfizer Clinical Protocol, A Phase 3 Study of SOU11248 in Combination with Paclitaxel versus Bevacizumab with Paclitaxel in the First-line Advanced Disease Setting in Patients having Breast Cancer. (per patient payment).
2008 a PFIZER Clinical protocol, Comparison of Sutent and Taxol versus Avastin and Taxol as first line

Therapy in Metastatic Breast Cancer. (per patient payment)


2009a NOVARTIS Clinical protocol, Bollerro trial in metastatic breast cancer. (per patient payment).
2010 CELLDEX Clinical protocol, CDX 011-03 trial in metastatic breast cancer. (per patient payment).
2011 GENENTECK and HOFFMAN-La ROCHE ltd, Emilia trial in metastatc breast cancer. (per patient

payment).


2011 AMGEN, D-Care clinical trial in adjuvant breast cancer. (per patient payment).
2011 NATIONAL INSTITUTES OF HEALTH, Menopause and related health effect of (Neo) adjuvant

Therapy for breast cancer. (Sub PI ).




PUBLICATIONS:
Original Observations in Journals:


  1. Martino S, Samal BA, Al-Sarraf M. Phase II study of 5 fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract. Cancer Treat Rep., 64(1):161-3, 1980.




  1. Samal BA, Brooks SC, Cummings G, Franco L, Hire EA, Martino S, Singhakowinta A, Vaitkevicius VK. Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer. 15;46 (12 Suppl):2925 2927, December 1980




  1. Martino S, Samal BA, Singhakowinta A. PCNU in advanced breast cancer. Cancer Treatment Rep. 1983 March; 67(3):305-6.




  1. Ownby H, Martino S, Russo J, Roi L, Brennan MF. Interrupted Pregnancy as an Indicator of Prognosis in Primary Breast Cancer. Breast Cancer Res Treat. 3(4):339 44,1983.




  1. Martino S, Samal BA, Singhakowinta A, Yoshida S, Mackenzie M, Jain J, Vaitkevicius VK. A Phase II Study of Cis Diamminedichloroplatinum II for Advanced Breast Cancer Utilizing Two Dose Schedules. J Cancer Res Clinical Oncology, 108(3):354 6, 1984.




  1. Muss HB, Kemp RA, Martino S, Rudnick SA, Greiner J, Cooper MR, Decker D, Grunberg SM, Jackson DV, and Richards F 2d. A Phase II Study of Recombinant Alpha Interferon in Patients with Recurrent or Metastatic Breast Cancer. JCO 2(9):1012 16, 1984.


Original Observations in Journals (continued):



  1. Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YH, Rudnick SA. Reversible Arrhythmias

Observed in Patients Treated with Recombinant Alpha 2 Interferon. J Cancer Res Clinical Oncology,

113(4):376 8, 1987.




  1. Martino S, Decker DA, Hines HE, Kresge C. Phase II Evaluation of Aclacinomycin A in Ovarian Carcinoma. Invest New Drugs, 5(4):373 374, December 1987.




  1. Ajluni S, Martino S, Singhakowinta A, Samal BA, Decker DA. Characteristics of Cranial Nerve Palsies

Due to Osseous Metastases in Metastatic Breast Cancer. Department of Medicine Bulletin, 2(1):23 26, 1988.


  1. Apel J, Singhakowinta A, Martino S, Samal BA, Bergsman K, Vaitkevicius V. Repeat Combination Chemotherapy Following Adjuvant Use in Advanced Breast Cancer. Department of Medicine Bulletin, 2(1):46 51, 1988.




  1. Martino S, Ratanatharathorn V, Samal BA, Singhakowinta A. Treatment of Metastatic Breast Cancer with AZQ: A Phase II Trial. Cancer Invest, 6(3):289 91, 1988.




  1. Gala R, Martino S, Wiejowski SA, Kresge CL, Alonso MDM. Serum Interleukin 2 (IL 2) Levels and Prolactin Bioactive/Radio-Immunoassay Ratios of Women at Risk for Breast Cancer. Eur J Cancer Clin Oncology, 25(11):1603 5, November 1989.




  1. Flaherty LE, Redman BG, Chabot GG, Martino S, Gualdoni SM, Heilbrun LK, Valdivieso M, and Bradley EC. A Phase I II Study of Dacarbazine in Combination With Outpatient Interleukin 2 in Metastatic Malignant Melanoma. Cancer, 65(11):2471 2477, June 1, 1990.




  1. Redman BG, Flaherty LE, Chou T, Al Katib A, Kraut MJ, Martino S, Chen B, Kaplan J, Valdivieso M.

A Phase I Trial of Recombinant Interleukin 2 Combined With Recombinant Interferon Gamma in Patients With Cancer. J Clinical Oncology, 8:1269 1276, 1990.


  1. Martino S, Samal B, Redman B, Flaherty L, Kraut M, Simon M, Valdivieso M. Phase II Study of Deoxydoxorubicin in Previously Untreated Breast Cancer. Breast Cancer Res Treat,17(2):139 143, December 1990.




  1. Djuric Z., Heilbrun LK, Reading BA, Boomer A, Valeriote FA, Martino S. Effects of a Low Fat Diet on Oxidative DNA Damage Levels in Human Peripheral Nucleated Blood Cells. J National Cancer Inst., 83(11):766 769, June 5, 1991.




  1. Cowan, J.D., Neidhart, J., McClure, S., Coltman Jr., C.A., Gumbart, C., Martino, S., Hutchins, L.F., Stephens, R.L., Vaughan, C.B., Osborne, C.K. Randomized Trial of Doxorubicin, Bisantrene, and Mitoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study. J National Cancer Inst, 83(15):1077 1084, August 7, 1991.




  1. Flaherty, L., Wozniak, A., Redman, B., Kraut, M., Martino, S., Heilbrun, L, Valdivieso, M. 5 FU,

Etoposide and Cisplatin in the Management of Metastatic Non Small Cell Lung Cancer. Cancer, 68(5):944-947, September 1991.


  1. Simon, M.S., Schwartz, A.G., Martino, S., Swanson, G.M. Trends in the Diagnosis of Insitu Breast Cancer in the Detroit Metropolitan Area, 1973 1987. Cancer, 69(2):466-469, January 15, 1992.




  1. Simon, M.S., McKnight, E., Schwartz, A., Martino, S., Swanson, G.M. Racial 1991, Differences in Cancer of the 1991, Male Breast - 15 year experience in the Detroit Metropolitan Area. Breast Cancer Res Treat, 21(1):55-62, 1992.




  1. Redman, B., Flaherty, L., Chou, T.H., Kruat, M., Martino, S., Simon, M., Valdivieso, M., Groves, E. Phase I trial of recombinant macrophage colony stimulating factor. J. Immunother 1992 Jul;12(1):50-54, July 1992.


Original Observations in Journals (continued):


  1. Redman, B.G., Flaherty, L., Martino, S., Kraut, M., Wisniewski, C., Valdivieso, M., Bander, J.J. Effect of Calcium Replacement on the Hemodynamic Changes Associated With High Dose Interleukin 2 Therapy. Am J Clin Onc 1992 Aug;15(4):340-3.




  1. Kasim, S.E., Martino, S., Paik-Nyon, K., Khilinani, S., Boomer, A., Depper, J., Reading, B.A., Heilbrun, L.K. Dietary and anthropometric determinants of plasma lipoproteins during a long-term low-fat diet in healthy women. Amer J of Clin Nutri 1993 Feb;57(2):146-53.




  1. Flaherty, L.E., Robinson, W., Redman, B.G., Gonzalez, R., Martino, S., Kraut, M.J., Valdivieso, M., Rudolph, A.R. A Phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993 Jun 1;71(11):3520-5.




  1. Simon, M.S., Hoff, M., Hussein, M., Martino, S., Walt, A. An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology. Breast Cancer Res Treat1993 Sept;27(3):211-9.




  1. Simon, M.S., Lemanne, D, Schwartz, A.G., Martino, S., Swanson, M. Recent Trends in the Incidence of In Situ and Invasive Breast Cancer in the Detroit Metropolitan Area (1975 1988). Cancer1993 Feb 1;71(3):769-74.




  1. Chlebowski, R.T., Blackburn, G.L., Buzzard, I.M., Rose, D.P., Martino, S., Khandekar, J.D., York, M.R., Jeffery, R.W., Elashoff, R.M., Wynder, E.L. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. Journal of Clinical Oncology,11 (11):2072-80, 1993.




  1. Ensley J, Weaver D, Benitez P, An T, Maciorowski Z, Alonso M, Kukuruga M, Martino S. Dietary Modulation of Abnormal DNA Histograms From Breast Aspirates of Patients at High Risk for Developing Breast Cancer. Cancer Molecular Biology 1994 Jan-Feb;1:45-51.




  1. Fabian CJ, Kimler BF, McKittrick R, Park CH, Lin F, Krishnan L, Jewell WR, Osborne CK, Martino S, Hutchins LF, Leong LA, Green S. Recruitment with high physiologic doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancer. Cancer Res 1994 Oct 15;54(20):5257-62.




  1. Ravdin PM, Green S, Doroshow JH, Martino S. Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group Study. Investi New Drugs 1994;12(4): 333-6.




  1. Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O'Sullivan J, Osborne CK. Short Course FAC-M vs. 1 year of CMFVP in Node-Positive, Hormone-Receptor Negative Breast Cancer: an Intergroup Study. J Clin Oncol 1995 April;13(4)831-9.




  1. Djuric Z, Heilbrun LK, Simon MS, Smith D, Luongo DA, LoRusso PM, Martino S. Levels of 5-Hydroxymethyl-2'-Deoxyuridine in DNA from Blood as a Marker of Breast Cancer. Cancer 1996 Feb 15;77(4):691-6.




  1. Albain KS, Green SR, Lichter AS, Hutchins LF, Wood, WC Henderson IC, Ingle JN, O'Sullivan J, Osborne CK, Martino S. Influence of Patient Characteristics, Socioeconomic Factors, Geography and Systemic Risk on the Use of Breast Sparing Treatment in Women Enrolled in Adjuvant Breast Cancer Studies: An Analysis of Two Intergroup Trials. J Clin Oncol 1996;14(11):3009-17.




  1. Simon MS, Heilbrum LK, Boomer A, Kresge C, Depper J, Kim PN, Valeriote F, Martino S. A Randomized Trial of a Low-Fat Dietary Intervention in Women at High Risk for Breast Cancer. Nutr Cancer 1997;27(2),136-42.


Original Observations in Journals (continued):


  1. Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol Acetate and Aminoglutethimide/ Hydrocortisone in Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer: A Southwest Oncology Group Phase III Trial. J Clin Oncol 1997;15(7):2494-2501.




  1. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK. bc1-2, p53, and Response to Tamoxifen in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study. J Clin Oncol 1997;15(5):1916-22.




  1. Ramnath N, LoRusso P, Simon M, Martino S. Phase II Evaluation of Cisplatin and WR2721 for Refractory Metastatic Breast Cancer. Am J Clin Oncol 1997 Aug;20(4):368-72.




  1. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron P, Gamagami P, Waisman JR. Outcome After Invasive Local Recurrence in Patients with Ductal Carcinoma in Situ of the Breast.

J Clin Oncol 1998 Apr;16(4)1367-73.


  1. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert N, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK. A Multi-Center Randomized Clinical Trial Of Goserelin vs. Surgical Ovariectomy In Pre-Menopausal Patients With Receptor Positive Metastatic Breast Cancer: An Intergroup Study. J Clin Oncol 1998 March; 16(3)994-99.




  1. Elledge RM, Green S, Ciocca D, Pugh R, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK. HER-2 expression and response to tamoxifen in estrogen recetor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 1998 Jan;4(1)7-12.




  1. Djuric Z, Depper JB, Uhley V, Smith D, Lababidi S, Martino S, Heilbrun LK. Oxidative DNA damage levels in blood from women at high risk for breast center are associated with dietary intake of meats, fruits and vegetables. J Am Diet Assoc May 1998;98(5)524-28.




  1. Ciocca D, Green SJ, Elledge R, Clark G, Pugh R, Ravdin P, Lew D, Martino S, Osborne CK. Heat shock proteins, Hsp27 and Hsp 70: Lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study. Clinical Cancer Research 1998 May;4(5)1263-1266.




  1. Early Breast Cancer trialist Collab. Group (Martino S for SWOG). Tamoxifen for early breast cancer: an overview of the randomized trials: Lancet 1998 May; 351(9114)1451-67.




  1. Geyer CE Jr, Green S, Moinpour CM, Sullivan J, Goodwin DK, Canfield VA, Meyers FJ, Martino S. Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group Study. Breast Cancer Res Treat 1998 Sept;51(2)169-81.




  1. Early Breast Cancer Trialist, Collabarative. Group, (S. Martino, for SWOG) Polychemotherapy for early breast cancer: an overview of the randomized trials: Lancet 1998 Sept;352(9132):930-42.




  1. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999 May;340(19):1455-61.




  1. Ellis GK, Green S, Livingston RB, Pierce HI, Paradelo JC, Taylor SA, Martino S. Neo-FAC" (5-fluorouracil, doxorubicin and cyclophosphamide) for poor prognosis stage IV breast cancer: A Southwest Oncology Group Phase II Study. Am J Clin Oncol 1999 Oct;22(5):446-49.




  1. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar G, Spitzer G, Swain SM, Vaughn CB, Vogel C, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clinical Transplant 2000 Feb;14(1):32-41.

Original Observations in Journals (continued)



  1. Elledge RM, Green S, Pugh R, D. Allred C, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK. ER and PgR Ligand binding assay compared with ER, PgR and pS2 by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000 March 20;89((2);111-17.




  1. Stadtmauer EA, Neill, AO, Goldstein LJ, Crilley PA, Mangan, KF, Ingle JN, Luger SM, Klumpp TR, Brodsky I, Litzow MR, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional dose chemotherapy compared to high dose chemotherapy with autologous stem cell transplantation in the management of responding metastatic breast cancer: The Philadelphia Intergroup Trial (PBT-1). N Engl J Med 2000 Apr 13;342(15):1069-76.




  1. Early Breast Cancer Trialists Collab. Group, (S. Martino, for SWOG) Favorable and unfavorable effects on long–term survival of radiotherapy for early breast cancer: an overview of the randomized trials, The Lancet 2000 May 20; 355(9712):1757-70.




  1. Page D, Gray R, Allred DC, Dressler L, Hatfield A, Martino S, Robert N, Wood W. Prediction of node negative C Outcome by histologic grading and S-phase analysis by flow cytometry: An ECOG study (2192). Am J Clin Oncol 2001 Feb;24 (1):10-18.




  1. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002 June 5;94(11):855–57.



  1. Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Adjuvant Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil, Vincristine, and Prednisone compared with Single-Agent L-Phenyulalanine Mustard for Patients with Operable Breast Cancer and Positive Auxillary Lymph Nodes. Cancer. 87(1):21-9, January 1, 2003.




  1. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein L, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei III E, Schlinsky RL, Wood WC. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003 March 15;21(6)976-83.




  1. Ellerbroek N, Martino S, Mautner B, Tao ML, Rose C, Botnick L. Breast-Conserving Therapy with Adjuvant Paclitaxel and Radiation Therapy: Feasibility of Concurrent Treatment. The Breast Journal, 2003, 9(2)74-8.



  2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, and Norton L. Randomized trial of dose dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003 April 15;21(8)1431-1439.




  1. Sledge G, Neuberg D, Bernardo P, Ingle J, Martino S, Rowinsky E, Wood W. Phase III Trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003 February 15;21(4) 588-592.




  1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 2003 Nov 6;349(19):1793-1802.




  1. Martino S, Costantino J, Secrest R, McNabb M, Bryant K, Powles T, Mershon J. The role of selective estrogen receptor modulators in the prevention of breast cancer: Comparison of the clinical trials. The Oncologist 2004; 9:116-125.


Original Observations in Journals (continued):


  1. Lyman GH, Green S, Ravdin PM, Geyer CE Jr, Russell CA, Balcerzak SP, Budd GT, Martino S. A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. Breast Cancer Research and Treatment 2004; 85:143-150.




  1. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the NCCTG N9831 intergroup adjuvant trial. Journal of Clinical Oncology 2004; 22(18):3700-3704.



  2. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of Raloxifene. Journal of the National Cancer Institute 2004; 96(23):1751-1761.



  3. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study. Clinical Cancer Research 2004; 10:5670-5676.




  1. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Robert, NJ, Martino S, Tripathy D, Ingle JN, Wood WC for ECOG, SWOG, CALGB and NCCTG. Efficacy of radiotherapy for ovarian ablation: Results of a breast intergroup study. Cancer 2004; 101(5):969-972.




  1. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR. RESPONSE – Correspondence: Yalcin B, Buyukcelik, Yalcin S, et. al Re:Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of Raloxifene. Journal of the National Cancer Institute 2005; 97(7):542-543.




  1. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of Raloxifene over eight years in a clinical trial setting. Current Medical Research and Opinion 2005; 21(9):1441-1452.




  1. Davidson NE, O’Neill AM, Vukor AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). Journal of Clinical Oncology 2005; 23(25):5973-5982.




  1. Whelan T, Goss P, Ingle J, Pater J, Dongsheng T, Pritchard K, Liu S, Shepherd L, Palmer M, Tu D, Robert N, Martino S, Muss H. Assessment of quality of life in MA.17: A randomized placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology 2005; 23(28): 6931-6940.




  1. Goss PE, Ingle JN, Martino S, Robert NJ, Hyman B, Piccart MJ, Castiglione M, Dongsheng T, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Letrozole following taxomifen as extended adjuvant therapy in receptor positive breast cancer: NCIC CTG MA.17. J Natl Cancer Inst 2005; 97(17):1262-1271.




  1. Romond, EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Improved outcome with the addition of adjuvant trastuzumab to adjuvant chemotherapy in her2-positive breast cancer combined anlysis of NSABP B-31 and NCCTG N9831. New England Journal of Medicine 2005; 353:1673-1684




  1. Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized controlled trial of CMF versus CAF with and without Tamoxifen for high-risk, node negative breast cancer: Treatment results of intergroup protocol INT-0102. J Clin Oncol 2005;23(33):8313-8321.



Original Observations in Journals (continued):


  1. Unger JM, Coltman Jr CA, Crowley Jj, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crwaford ED, Albain KS. Impact of the Year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 2005;24(1):141-144.




  1. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein L, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 2006;295(14):1658-1667.

  2. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central and reference laboratories in 1823 specimens from the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 2006; 24(19):3032-3038.




  1. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu SF, TU D, Goss PE. Effect of Letrozole versus Placebo on Bone Mineral Density in Women with Primary Breast Cancer Completing Five or More years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. J Clin Oncol 2006; 24(22):3629-3635.




  1. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams J, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99(3):295-300




  1. Lippman ME, Cummings SR, Kisch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006;12(17):5242-5247




  1. Umetani N, Giuliano AE, Hiramatsu S, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of Lymph Node Metastases of Breast Cancer by Inegrity of Free Circulating DNA in Serum. J Clin Oncol. 2006;24(26):4270-4276.




  1. Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007, 25(13):1677-82




  1. Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced vs. Simultaneous Anthracycline and Cyclophosphamide in High Risk Stage I-II Breast Cancer: Final Analysis From INT-0137 (S9313). Journal of Clinical Oncology 2007, 25(6): 656-661.




  1. Gotay CC, Moinpour CM, Unger JM, Jiang C, Ankerst DP, Coleman D, Martino S, Parker B, Bearden J, Dakhil S, Gross H, Lippman S, Albain KS.Impact of a Peer-Delivered Telephone Intervention for Women Experiencing a Breast Cancer Recurrence. J Clin Oncol. 2007, 25(15):2093-9.




  1. Hayes DF, Thor A, Dressler L, Weaver D, Edgerton S, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC, Berry D. HER2 and response to paclitaxel in node-positive breast cancer.. N Engl J Med. 2007, 357(15):1496-506.




  1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007, 25(15):2006-11.




  1. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008,19(5):877-82.


Original Observations in Journals (continued):


  1. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008, 358(16):1663-71.




  1. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008, 26(8):1231-8.




  1. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol. 2008, 26(8):1223-30.




  1. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008, 26(12):1956-64.




  1. Goss PE, Ingle, JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione, Tu D, Shepherd LE, Pritchard KL, Lingingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Dongsheng T. Late Extended adjuvant treatment with Letrozole improves outcome in women with early-stage breast cancer after completing five years for Tomaxifen. Journal of Clinical Oncology 26(12): 1948-1955, 2008.




  1. Goodwin JW, Green SJ, Moinpour CM, Bearden JD, Giguere JK, Jiang CS, Lippman SM, Martino S, Albain KS. A phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for sympotom of ovarian failure in women treated for breast cancer: Southwest Oncology Group Study 9626. J Clin Onc. 2008, 26(10): 1650-1656.




  1. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez ED, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008, 26(20):3472.




  1. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008, 26(25):4063-4071




  1. Goldstein L, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, and Davidson N. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008, 26(25):4092-4099.



  2. Halyard MY, Pisansky TM, Dueck A, Pierce LG, Solin LJ, Marks LB, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Dakhil SR, Perez EA. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer: Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase 3 Trial N9831 J Clin Oncol. 2009, 27(16):2638-2644




  1. Hershman DL, Unger JM, Barlow W, Hutchins L, Martino S, Osborne K, Livingston R, and Albain KS. Treatment Quality and Outcomes of African American versus Caucasian Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Group Studies S8814/S8897. J Clin Oncol. 2009, 27(13):2157-2162.


Original Observations in Journals (continued):


  1. Choi JY, Barlow WE, Albain K, Hong C-C, Blanco JG, Livingston R, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin P8, Martino S, Lyss AP, Osborne K, Abeloff M, Hayes DF, Ambrosone CB. Nitric oxide synthase (NOS3) variants and disease-free survival among treated and untreated breast cancer patients in a SWOG Clinical Trial (S8897). Clin Cancer Res. 2009, 15(16):5258-5266.




  1. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh I-T, Choi J-Y, Davis W, Rae JM, Tang L, Hutchins L, Ravdin P, Martino S, Osborne CK, Lyss AP, Hayes DF, and Albain KS. Myeloperoxidase Genotypes and Enhanced Efficacy of Chemotherapy for Early Stage Breast Cancer in SWOG 8897. J Clin Oncol. 2009, 27(30):4973-4979.




  1. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner R, Bugarini R, Rowley S, Perez EA, Shulman L, Martino S, Davidson NE, Sledge GW, and Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009, 15(24):7693-7700.




  1. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingtston RB, Martino S, Perez E, Hortobagyi, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy in breast cancer (S0012): A South West Oncology Group Study. Breast Cancer Res Treat. 2010, 119(2):391-398.




  1. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal with endocrine-responsive, node-positive breast cancer: A phase 3, open-lable, randomised controlled trial. Lancet. 2010 (374): 2055-2063.




  1. Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Anne E. Wiktor, B.S.2, Patrick P. Bedroske, Anderson SK, Ketterlillng RP, Sukov WR, Manehira K, Beiyun Chen, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM. C-MYC Alterations and Association with Patient Outcome in Early-Stage HER2+ Breast Cancer from the NCCTG Adjuvant Trastuzumab Intergroup Trial N9831. J Clin Oncol. 2011 feb 20;29(6):651-9.



  2. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009, 15(24):7693-7700.



  3. Perez E, Reinholz M, Hillman D, Tenner K, Schroeder M, Davidson N, Martino S, Sledge G, Harris N, Gralow J, Dueck A, Ketterling R, Ingle J, Lingle W, Kaufman P, Visscher D. Jenkins R. HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 2010,28(28):4307-4315



  1. Perez, EA, Romond EH, Susman VJ, Jeong J-H, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four–year follow-up of transtuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer:joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology. 2011,29(25):3366-3373



  2. Lara J, Thor A, Dressler L, Broadwater G, Bleiweiss I, Edgerton S, Cowan D, Goldstein L, Martino S, Ingle J, Henderson I, Norton L, Winer E, Hudis C, Ellis M, Berry D, Hayes D. p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B(CALGB) 9344 Trial. Clinical Cancer Research. 2011, 17(15):5170-5178









    Original Observations in Journals (continued):

  1. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini RL, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Jr., and Gray R. Relationship Between quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple Negative Breast Cancer. Clin Cancer Res. 2011 Nov 15;17(22): 7194-203



  2. Sparano J, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff A, Sledge G, Wood WC, Davidson NE. Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. J Natl Cancer Inst. 2012 Jan 16.(Epub ahead of print)



  3. Sparano J, Wang M, Stearns V, Martino S, Perez E, Saphner T, Wolff A, Sledge G, Wood W, Fetting J, Davidson N. Obesity at diagnosis is associated with inferior outcomes in hormone receptor operable breast cancer. ( accepted by JCO January 2012)



  4. Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, Shamonki JM, Martino S, Cui X, Giuliano AE. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol. 2012 Mar;19(3):935-40



  5. Schneider B, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez E, Saphner T, Wolff A, Sledge G, Wood W, Davidson N, Sparano J. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. ( accepted for publication by Journal of Clinical Oncology, January 2012).



  6. Solin L, Gray R, Goldstein L, Recht A, Baehner F, Shak S, Badve S, Perez E, Shulman L, Martino S, Davidson N, Sledge G, Sparano J. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast cancinoma: results from the Eastern Cooperative Oncology Group E2197 Study. ( accepted by Breast Cancer Research and Treatment, April 2012).




  1. Sukov W Reinholz M, Hillman D, Dueck A, Miller D, Tenner K, Ketterling R, Kaufman P, Davidson N, Dakhil S, Martino S, Andorfer C, Jenkins R, Perez E. Benefit of Adjuvant Trastuzumab in Breast Cancer Patients with Focal HER2 Amplified Clones: Data from the N9831 Trastuzumab Adjuvant Trial. ( accepted by Clinical Cancer Research, 3-2012)




  1. Perez E, Martino S. C-MYC Protein Expression and Gene Amplification and Association with Patient Outcome in Early-Stage HER+ Brest Cancer from the North Central Cancer Treatment Group Adjuvant Trastuzumab Trial N9831. (accepted for publication 8-12 JCO)

  2. Perez E, Dueck A, McCullough A, Chen B, Geiger X, Jenkins R, Lingle W, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Harris L, Gralow J, Andorfer C, Reinholz M. Impact of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831, (submitted to J Clin Onc, 1-2012)




  1. Patel T, Moreno-Aspitia A, Kutteh L, Jaffe A, Hobday T, LaPlant B, Hillman D, Gersh B, Rodeheffer R, Kaufman P, Davidson N, Martino S, Perez E. Role of Circulating Cardiac Markers from the Adjuvant N9831Clinical Trial. (accepted by American Association for Cancer Research, December,2011)




  1. Sparano J, Goldstein L, Childs B, Yoshizawa C, Watson D, Rowley S, Shak S, Badve S, Baehner F, Davidson N, Sledge G, Perez E, Shulman L, Martino S, Gray R. Association of individuals genes associated with recurrence in operable breast cancer treated with adjuvant chemotherapy. (In preparation




  1. Shulman L, Cirrincione C, Berry D, Becker H, Perez E, O’Regan R, Martino S, Atkins J, Mayer E, Schneider C, Kimmick G, Norton L, Muss H, Winer E, Hudis C, Six cycles of doxorubicin and cyclophophamide or paclitaxel are not superior to 4 cycles as adjuvant chemotherapy for breast cancer in women with 0-3 positive axillary nodes. (published ahead of print on July 23, 2012, JCO)






  1. Goss P, Ingle J, Martino S, Tobert N, Muss H, Livingston R, Davidson N, Perez E, Cameron D, Pritchard K, Whelan T, Shepherd L, Tu D. Analysis of women premenopausal at diagnosis entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant Letrozole. (submitted to Lancet Oncology, March 2012))









Yüklə 231,71 Kb.

Dostları ilə paylaş:
  1   2   3   4




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2022
rəhbərliyinə müraciət

    Ana səhifə